Catalent Acquires Juniper Pharmaceuticals

Acquisition strengthens Catalent's global early-phase development capabilities

Jefferson2

Nottingham, U.K.-based dose form development and clinical manufacturing specialist, Juniper has been added as a European Early Development Center of Excellence to Catalent’s global network. When combined with Catalent’s existing centers of excellence for early drug development in the U.S. and Europe, the acquisition of Juniper expands and strengthens Catalent’s offerings and complements its integrated global clinical and commercial supply network.

Read full press release here.
Download more details here.
Learn more about Career Opportunities in Nottingham

Juniper's commitment to science-based, solutions oriented development and to quality and operational excellence fits well with Catalent’s data-driven, consultative approach to early development. Catalent’s pharmaceutical customers will now be able to take advantage of accelerated and comprehensive clinical development and manufacturing capabilities at a location of their choice with seamless scale up to later clinical stages and commercial launch capabilities within Catalent's global network.

DissolvingMolecule_380x380

Learn more about Catalent’s Early-Phase Development Capabilities, including:

About Juniper Pharmaceuticals

A UK-based development partner focused on formulation and analytical development and early-phase clinical manufacturing of complex, small-molecule compounds, Juniper offers science-driven innovation and a portfolio of solutions to help customers reduce risk and accelerate their key drug development programs from discovery to the clinic. Offerings include:

Contact Us to find out about how we can help solve your development challenges.

*The services described on this page are supplied in the U.K. by a wholly owned subsidiary of Catalent named Juniper Pharma Services Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX, U.K.